Entera Bio (ENTX) Cost of Revenue (2019 - 2025)

Entera Bio (ENTX) has 6 years of Cost of Revenue data on file, last reported at $42000.0 in Q1 2025.

• Quarterly Cost of Revenue changed N/A year-over-year to $42000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $42000.0 (down 75.58% YoY) and the FY2025 annual result came in at $42000.0, down 75.58% from the prior year.
• Cost of Revenue declined to $42000.0 in Q1 2025, from $82000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $136000.0 in Q4 2021 to a low of $6000.0 in Q3 2022.
• A 4-year average of $57333.3 and a median of $51000.0 in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2021 — Cost of Revenue surged 219.35% — and 2022, when it sank 94.12%.
• Tracing ENTX's Cost of Revenue over 4 years: stood at $136000.0 in 2021, then slumped by 94.12% to $8000.0 in 2022, then soared by 925.0% to $82000.0 in 2024, then tumbled by 48.78% to $42000.0 in 2025.
• The last three Cost of Revenue figures came in at $42000.0 (Q1 2025), $82000.0 (Q4 2024), and $42000.0 (Q3 2024), per Business Quant data.